Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 2/20 | 0.47 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19974935 | 0.87 | HPGD (0.44) | SMN1; SMN2NPC1RAB9AP2RX7ALDH1A1 | |
| SCHEMBL21183512 | 0.87 | P2RX7 (0.43) | NPC1RAB9ACNR2P2RX7CNR1 | |
| SCHEMBL21183528 | 0.86 | SMN1; SMN2 (0.57) | SMN1; SMN2P2RX7ALDH1A1KDM4ELMNA | |
| SCHEMBL19974961 | 0.86 | POLB (0.45) | SMN1; SMN2RAB9AALDH1A1KDM4EGAA | |
| SCHEMBL28316787 | 0.84 | F10 (0.41) | SMN1; SMN2ALDH1A1KDM4EKMT2A | |
| SCHEMBL19975412 | 0.84 | HPGD (0.49) | SMN1; SMN2CNR2P2RX7ALDH1A1KDM4E | |
| SCHEMBL19975275 | 0.83 | F10 (0.47) | SMN1; SMN2ALDH1A1KDM4ELMNAKMT2A | |
| SCHEMBL19974941 | 0.81 | POLB (0.51) | SMN1; SMN2NPC1RAB9AP2RX7ALDH1A1 | |
| SCHEMBL19975297 | 0.80 | CHRM2 (0.40) | CNR2P2RX7ALDH1A1GAALMNA | |
| SCHEMBL19974873 | 0.80 | SMN1; SMN2 (0.48) | SMN1; SMN2NPC1RAB9ACNR2P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220356148-A1 | ANTIVIRAL COMPOUNDS | HAPLOGEN GMBH (AT) | 2022-11-10 | — | — | US | disclosed |
| US-11091428-B2 | Antiviral compounds | HAPLOGEN GMBH (AT) | 2021-08-17 | — | — | US | disclosed |
| US-11091428-B2 | Antiviral compounds | HAPLOGEN GMBH (AT) | 2021-08-17 | — | — | US | disclosed |
| CN-110062753-A | Antiviral compounds | 哈普洛根有限责任公司 | 2019-07-26 | — | — | CN | disclosed |
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | LUNIS CONSULTING GMBH (AT) | 2019-07-25 | — | — | US | disclosed |
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | LUNIS CONSULTING GMBH (AT) | 2019-07-25 | — | — | US | disclosed |
| EP-3512836-A1 | ANTIVIRAL COMPOUNDS | Haplogen GmbH (AT) | 2019-07-24 | — | — | EP | disclosed |
| WO-2018050631-A1 | ANTIVIRAL COMPOUNDS | HAPLOGEN GMBH (AT) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | PLA2G1B, PLA2G12A, PLA2G4C | SMN1; SMN2 706/4885NPC1 753/4885RAB9A 1576/4885 |
| US-20220356148-A1 | ANTIVIRAL COMPOUNDS | PLA2G12A, PLA2G1B, PLA2G4C | SMN1; SMN2 1086/4885NPC1 1213/4885RAB9A 1334/4885 |
| US-11091428-B2 | Antiviral compounds | PLA2G1B, PLA2G12A, PLA2G4C | SMN1; SMN2 706/4885NPC1 753/4885RAB9A 1576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.